Please assess the completion status of the following clinical trial:

Trial Title: Study of BIIB092 in Participants With Progressive Supranuclear Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants with probable or possible PSP~* Able to ambulate independently or with assistance~* Able to tolerate MRI~* Have reliable caregiver to accompany participant to all study visits~* Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at screening~* Participant must reside outside a skilled nursing facility or dementia care facility at the time of screening and admission to such a facility must not be planned~Key Exclusion Criteria:~* Presence of other significant neurological or psychiatric disorders~* Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neuron disease~* History of early, prominent rapid eye movement (REM) sleep behavior disorder~* History of or screening brain MRI scan indicative of significant abnormality~* Known history of serum or plasma progranulin level less than one standard deviation below the normal patient mean for the laboratory performing the assay~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 41 Years
- Maximum Age: 86 Years
- Healthy Volunteers: f

Study Arms:
- BIIB092 (Type: EXPERIMENTAL): Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.

Based on this trial design, predict the completion outcome and termination type (if applicable).